The healthcare sector, represented by the Health Care Select Sector SPDR Fund (NYSEARCA:XLV), underperformed the broader ...

While current methods of isolating islet cells for transplantation strip away the structural scaffold that supports the cells ...

Bristol-Myers Squibb faces revenue declines but offers long-term potential via growth drugs. Read what BMY stock has to offer ...

The FDA said risks linked to CAR-T cell therapies can be effectively communicated through existing labeling, including boxed ...

Enhanced treatment options, precision medicine, and advanced diagnostics are fueling growth across major markets Zollinger ...

Bristol Myers Squibb (BMY) closed at $47.51 in the latest trading session, marking a +2.64% move from the prior day.

Bristol Myers Squibb to cut 68 jobs in Lawrenceville as part of a broader restructuring effort aiming to slash $2B in costs ...

Cigna claims Bristol Myers’ Celgene unit filed sham lawsuits it knew it was unlikely to win in an effort to protect its ...

Bristol Myers Squibb Company (NYSE:BMY – Get Free Report) has received an average rating of “Hold” from the twenty-two brokerages that are presently covering the firm, MarketBeat reports. Two ...

If your physician prescribes a new branded drug, though, you and your insurance company have few options. Patent-protected ...

The mood is better than the numbers suggest. The doom-loop panic of March and April is behind us, even though the XBI has ...

FDA approved label changes for Breyanzi and Abecma, easing access by reducing monitoring rules and eliminating REMS safety ...